US REGULATORY RECORDS
- FDA API DMF records
- 9
- Active (A)
- 9
- Inactive (I)
- 0
FDA list cutoff:
ACTIVE PHARMACEUTICAL INGREDIENT
Research Upadacitinib API through FDA DMF and China CDE records. Compare reported companies, check registration status and confirm the chemical form before preparing a sourcing or dossier review.
Complete data requires an active subscription. Already subscribed? Sign in to access your data.
This Upadacitinib profile uses the anhydrous free-base reference identity, CAS 1310726-60-3. Explicit hemihydrate and intermediate subjects are excluded. Records are selected by reported substance name; neither source supplies a CAS field to verify the chemical form of every filing.
Upadacitinib registry coverage: 9 FDA API DMF entries and 30 CDE API registrations selected by substance name. Browse free samples, then subscribe to search, filter and export the complete available Upadacitinib records.
FDA list cutoff:
CDE export captured:
0 documented company-name correspondences
The registries have different snapshot dates and status definitions. Counts describe records, not qualified suppliers. Company fields retain their original wording, including repeated parties. No cross-registry company-name correspondences are documented for this profile.
$19.00 per month
$149.00 per year
Billed $149.00 every year
Upadacitinib coverage: 9 FDA DMF records and 30 CDE registrations. Free CSV samples contain the preview rows; a subscription opens the complete available records.
One personal account can access subscription datasets currently available on APIRFQ. Coverage varies by product. This does not include quotations, supplier qualification or live monitoring.
Use the Upadacitinib registry tables below to inspect original holder and company fields. No cross-registry company-name correspondences are documented. Similar names, translations or membership of the same group do not verify an identical legal entity or manufacturing site.
Free previewShowing 0 sample records of 0.
0 company-name correspondences
No exact company-name correspondences are documented for these snapshots.
Other records remain available below and in the registry tables. A missing name correspondence does not imply a missing registration.
Original reported names are preserved. A CDE company field may contain several named parties; their roles are not inferred from name order. Unmatched names are not treated as ineligible suppliers.
US REGULATORY RECORDS
Inspect Upadacitinib DMF holders, reported subjects, initial submission dates and activity codes. Compare the original fields before requesting dossier access. An active filing does not establish a qualified manufacturing site or an available batch.
9Active (A)
0Inactive (I)
A = active; I = inactive. DMFs are neither approved nor disapproved by FDA. These entries do not establish supplier qualification, manufacturing-site approval, dossier access or current availability.
Free previewShowing 3 sample records of 9.
Free preview
More records available with a subscription: 6.
CHINA REGULATORY RECORDS
Inspect Upadacitinib registration numbers, original Chinese company names, packaging and review status. Expand a record to read all eleven source columns. Separate registration numbers remain separate records even when the same enterprise is reported.
9Approved or qualifying prior approval (A)
21Technical review not passed or unlinked (I)
CDE A and I describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I means technical review has not been passed or the material has not been linked to a formulation registration. Reported validity dates and status do not independently establish current supplier qualification.
Free previewShowing 3 sample records of 30.
Free preview
More records available with a subscription: 27.
Upadacitinib, also known as ABT-494, is identified here by the anhydrous free-base CAS 1310726-60-3. The hemihydrate has a separate CAS, 2050057-56-0, and contains one water molecule per two drug molecules. These forms require different composition and assay checks. The reference identity defines this profile; an unqualified registry name does not establish the solid-state form or water content of a particular material.
Anhydrous reference identity; the CAS of each individual filing has not been independently verified.
The Upadacitinib formula and reference molecular weight below describe the anhydrous molecule. Hydration changes composition and mass. For a material comparison, request the stated chemical form, water content, assay basis and impurity specification from the relevant manufacturer. Registry packaging fields describe reported pack sizes rather than purchase quantities or current stock.
Use these official references to check Upadacitinib identifiers, distinguish the hemihydrate and interpret the two registries.
Check Upadacitinib CAS, formula, molecular weight and the ABT-494 synonym.
Read the sponsor table separating anhydrous Upadacitinib from the hemihydrate.
Check how a dossier is referenced and why an active listing does not establish approval.
Read the regulator explanation of A and I before comparing Chinese registrations.
This Upadacitinib profile uses anhydrous free-base CAS 1310726-60-3, formula C17H19F3N6O and PubChem CID 58557659. ABT-494 is a reported synonym. These are reference identifiers for the page, while the registry entries are selected by name and do not individually supply CAS confirmation.
Upadacitinib hemihydrate has CAS 2050057-56-0 and includes half a water molecule per drug molecule. The anhydrous reference has CAS 1310726-60-3. Explicit hemihydrate filings are excluded here. Confirm the intended form, water content and assay basis before comparing specifications or requesting a sample.
The supplied Q2 2026 list yields 9 Type II records whose subjects match UPADACITINIB after trimming whitespace for selection. Original subject text remains intact. Three intermediate subjects and six hemihydrate subjects are excluded. A Type II designation also covers intermediates, so matching the keyword alone is insufficient.
No. FDA A means active and I means inactive. FDA states that DMFs are neither approved nor disapproved. An Upadacitinib listing does not establish supplier qualification, manufacturing-site approval, permission to reference the dossier or current availability. Verify the official record and request the documentation relevant to your application.
The supplied export contains 30 registrations named exactly 乌帕替尼. Upadacitinib records retain all eleven source fields, including original enterprise names, packaging and unfilled specifications. Distinct registration numbers are counted separately; several belong to the same reported enterprise. The export does not provide a CAS field to confirm each registration’s chemical form.
For Upadacitinib registrations, CDE codes describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I covers technical review not passed or a registration not yet linked to a formulation. Use the snapshot date and current official record when interpreting either code.
Use the Upadacitinib records to identify reported parties and dossier references, then verify the legal entity, manufacturing site, exact chemical form, specification and right to reference the relevant dossier with the company. Request supporting batch and analytical documents for your intended use. A registry listing alone does not establish these points.
The free Upadacitinib preview shows a limited sample from each registry and provides matching CSV samples. Overview counts describe the complete selected dataset. A subscription enables the remaining available records, search, status filtering and complete CSV exports. It does not provide quotations, supplier qualification or live registry monitoring.
Primary references for chemical identity, registration records and status definitions. Open each source to check its scope and current information.
National Center for Biotechnology Information, U.S. National Library of Medicine
Reports the molecular formula, reference molecular weight, anhydrous CAS and ABT-494 synonym for CID 58557659.
“C17H19F3N6O”
National Center for Biotechnology Information, U.S. National Library of Medicine
Molecular formula in PubChem CID 58557659.
Pharmaceuticals and Medical Devices Agency; dossier submitted by AbbVie
The sponsor dossier distinguishes anhydrate CAS 1310726-60-3 from hemihydrate CAS 2050057-56-0 and gives the hydrate composition.
“1310726-60-3 (anhydrate)”
Pharmaceuticals and Medical Devices Agency; dossier submitted by AbbVie
AbbVie clinical overview hosted by PMDA, section 2.7.1, Table 2.7.1-1, printed page 10 (PDF page 10).
U.S. Food and Drug Administration
The selected filings come from the supplied second-quarter workbook, with a June 30, 2026 cutoff. The official page may offer a later quarterly list.
“UPADACITINIB”
U.S. Food and Drug Administration
Reported subject of the selected Type II records in worksheet 2Q2026-EXCEL; DMF 40344 retains its original trailing space.
U.S. Food and Drug Administration
Explains DMF use and review. A listing or active status does not establish approval of a supplier or product.
“Are neither approved nor disapproved.”
U.S. Food and Drug Administration
FDA statement about DMFs; their technical contents are reviewed with applications that reference them.
U.S. Food and Drug Administration
Type II is broader than APIs, so the reported subject must also be checked.
“Type II Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation; or Drug Product”
U.S. Food and Drug Administration
FDA Type II category heading.
Center for Drug Evaluation, National Medical Products Administration
The October 5, 2026 export supplies the name-selected registrations, with original Chinese company names, status codes, packaging, dates and blank fields.
“乌帕替尼”
Center for Drug Evaluation, National Medical Products Administration
Exact substance name of the selected registrations in the supplied eleven-column CSV.
Liaoning Medical Products Administration
Official explanation of A and I, including joint review, qualifying prior approvals and independent API review.
“未通过技术审评或尚未与制剂注册进行关联的标识为“I”。”
Liaoning Medical Products Administration
Regulator explanation published February 18, 2025: I covers technical review not passed or a registration not yet linked to a formulation.
Compare Upadacitinib registry names, review codes and chemical-form boundaries using the free samples. Subscribe to search, filter and export the complete available FDA and CDE records for your sourcing review.
Complete data requires an active subscription. Already subscribed? Sign in to access your data.
Report an Upadacitinib data issue with the page address, registry number and supporting official evidence. APIRFQ support handles data corrections. Contact the relevant company separately about material specifications, dossier access or supply.
Contact data support